Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389814 | 1.00 | GRIK1 (0.53) | GRIK1GRIK2GRIK3GRIA1GRIA2 | |
| SCHEMBL15389812 | 1.00 | GRIK1 (0.53) | GRIK1GRIK2GRIK3GRIA1GRIA2 | |
| SCHEMBL5079189 | 0.89 | PPARA (0.59) | GRIK1PPARGPPARASLC1A5KIF11 | |
| SCHEMBL5079192 | 0.89 | PPARA (0.59) | GRIK1PPARGPPARASLC1A5KIF11 | |
| SCHEMBL10420699 | 0.86 | PPARA (0.52) | GRIK1PPARGPPARASLC1A5KIF11 | |
| SCHEMBL10419212 | 0.86 | PPARA (0.52) | GRIK1PPARGPPARASLC1A5KIF11 | |
| SCHEMBL27255434 | 0.84 | BHMT (0.49) | PPARGPPARAKIF11 | |
| SCHEMBL25356342 | 0.83 | GRIK1 (0.54) | GRIK1GRIK2GRIK3GRIA1GRIA2 | |
| SCHEMBL1768639 | 0.83 | SLC7A5 (0.67) | GRIK1GRIK2GRIK3GRIA1GRIA2 | |
| SCHEMBL9394667 | 0.83 | SLC7A5 (0.67) | GRIK1GRIK2GRIK3GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-11-14 | — | — | US | claimed |
| WO-2024148312-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | WO | claimed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| CN-112672747-B | Peptides for activating cell signaling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024263637-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-27 | — | — | US | disclosed |
| WO-2024148312-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | disclosed |
| EP-0822827-B1 | ANTAGONISTS OF LHRH | UNIV TEXAS (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0822827-A4 | ANTAGONISTS OF LHRH | UNIV TEXAS (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0822827-A1 | ANTAGONISTS OF LHRH | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033729-A1 | ANTAGONISTS OF LHRH | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | DDC, AADAT, TYR | GRIK1 1212/4885GRIK2 848/4885GRIK3 775/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | GRIK1 2079/4885GRIK2 1986/4885GRIK3 2027/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | GRIK1 4649/4885GRIK2 4772/4885GRIK3 4522/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | GRIK1 4089/4885GRIK2 4198/4885GRIK3 4465/4885 |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | SCTR, CTRC, DCXR | GRIK1 4686/4885GRIK2 4629/4885GRIK3 4440/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | GRIK1 1782/4885GRIK2 2679/4885GRIK3 2004/4885 |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | DDC, AADAT, TYR | GRIK1 1212/4885GRIK2 848/4885GRIK3 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.